Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors
CA3328192A1Undetermined Publication Date: 2025-10-30BAYER AG
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CA3328192
- Authority / Receiving Office
- CA · CA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-04-22
- Filing Date
- 2025-04-22
- Publication Date
- 2025-10-30
Abstract
The invention refers to a co-crystal according to any one of formulae (I), (II), (III), (IV), (V), (VI) and / or (VII). Furthermore, the invention refers to a pharmaceutical formulation comprising any one of co-crystals according to formulae (I), (II), (III), (IV), (V), (VI) and / or (VII), the medical use of these co-crystals or the pharmaceutical formulation comprising such co-crystal(s) as well as to a process for preparing these co- crystals. The invention further refers to crystalline forms of and / or Empagliflozin as well as pharmaceutical comprising such crystalline forms.
Need to check novelty before this filing date? Find Prior Art
